Kornimate/medical-research-clean huggingface dataset:
caregiver burden in parkinson's disease

Conditions: Parkinson Disease

Summary: primary caregivers of patients diagnosed with idiopathic parkinson's disease will be included in the study. a total of 43 participants will be recruited. at the beginning of the study, demographic data and clinical characteristics of the patients, including disease stage, history of falls, presence of fractures, presence and severity of pain, comorbidities, and medication use, will be recorded. subsequently, caregivers' age, gender, occupation, relationship to the patient, caregiving duration, and their own comorbidities will be assessed. sleep problems will be evaluated using the insomnia severity index (isi), while symptoms related to depression and anxiety will be assessed with the hospital anxiety and depression scale (hads). caregiver burden will be examined using the zarit caregiver burden scale.


Eligibility criteria:
inclusion criteria: * age between 40-80 years * diagnosed with parkinson's disease, hoehn and yahr stage 2-5 * requires assistance in daily activities * informal caregiver providing care (unpaid, typically a family member such as a spouse or child) * caregiver has sufficient proficiency in turkish to understand and respond to the study questions exclusion criteria: * presence of any additional neurodegenerative disease other than parkinson's disease * diagnosis of chronic obstructive pulmonary disease (copd) * advanced heart failure classified as new york heart association (nyha) class iv (symptoms at rest) * active cancer disease * history of stroke causing limitations in daily life * immobility due to reasons other than parkinson's disease
the effect of graded motor imagery on pain and function in individuals with knee osteoarthritis

Conditions: Knee Osteoarthritis; Limitation, Mobility

Summary: the aim of this study is to investigate whether graded motor imagery (gmi) application is as effective as transcutaneous electrical nerve stimulation (tens) in individuals with knee osteoarthritis (oa). the objectives are to improve range of motion (rom) and muscle strength, reduce pain and stiffness, increase pain pressure threshold, and enhance function and physical performance through gmi application.

46 voluntary patients with knee oa, aged between 45-64 years will be randomly divided into two groups: gmi group and tens group. interventions will be applied for 8 weeks, 3 times a week (24 sessions). both groups will receive conventional physiotherapy and home exercises in addition to gmi or tens treatment. the patients will be assessed before, after treatment and six-week follow-up. knee pain will be evaluated using the visual analog scale (vas), pressure pain threshold will be measured using an algometer, pain, function, and stiffness will be assessed using the western ontario and mcmaster universities osteoarthritis index (womac), active knee range of motion will be measured using a digital goniometer, muscle strength will be evaluated using a hand-held dynamometer, and function will be assessed using the timed up and go test.

Eligibility criteria:
inclusion criteria: * minimum score of 24 on the mini mental state examination (indicating no mild or severe dementia) * diagnosis of moderate unilateral knee osteoarthritis persisting for more than 12 months according to american college of rheumatology (acr) criteria * experience of pain with a severity rating of 3 or higher on the visual analog scale (vas) for activities such as stair climbing, sitting, and squatting, lasting for at least 6 months (moderate to severe pain) * age between 45 and 64 years * residing in the city where the study is conducted * ability to walk independently * presence of limitations in knee range of motion (rom) * symptomatic and radiographically confirmed oa diagnosis of kellgren and lawrence grade i-iii exclusion criteria: * patients who are unwilling to participate in the study * patients presenting with secondary oa due to conditions such as rheumatoid arthritis, gout, septic arthritis, tuberculosis, tumor, trauma, hemophilia, major medical or psychiatric disorders, recent fractures, presence of effusion or open reduction and internal fixation in the knee * presence of a neuromuscular disease * history of intra-articular injections in the past 6 months * patients undergoing medication changes * presence of any chronic illness that would hinder participation in the treatment program * participation in a physiotherapy program for oa in the last 12 weeks * movement limitations or limb deficiency in the contralateral lower extremity * presence of visual or hearing problems that would affect treatment adherence.

Keywords: pain knee joint exercise range of motion muscle strength
the role of audiovisual biofeedback on image quality during 4d anatomic and functional imaging

Conditions: Lung Cancer

Summary: this study will investigate whether audiovisual biofeedback, in which visual and audio cues are used to regulate the patient's breathing, can increase the image quality of 4d ct and 4d pet scans.


Eligibility criteria:
inclusion criteria: required for inclusion in this study are: * informed consent * diagnosis of ajcc stage i-iii lung cancer of any histology to be treated using radiotherapy at stanford cancer center * age 18 or greater * painfree in supine position * karnofsky performance status 50 or greater the inclusion of educationally disadvantaged, decisionally impaired or homeless people are allowed if informed consent, in the opinion of the consenting investigator (study pi, co-pi or research nurse), is obtained. exclusion criteria: no * pregnant women * stanford employees * stanford students * prisoners will be eligible for the study.
chlorambucil compared with no further therapy following anti-helicobacter therapy in treating patients with low-grade lymphoma of the stomach

Conditions: Gastric Cancer

Summary: rationale: drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. it is not yet known whether chlorambucil is more effective than observation in treating low-grade lymphoma of the stomach. purpose: randomized phase iii trial to compare the effectiveness of chlorambucil with that of no further therapy following anti-helicobacter therapy in treating patients with low-grade lymphoma of the stomach.

objectives: i. determine the efficacy and response rate of triple antibiotic therapy for helicobacter pylori in the healing of lesions in patients with low grade gastric lymphoma. ii. assess the efficacy of chlorambucil in the prevention of relapse in patients after complete eradication of low grade gastric lymphoma. iii. determine the natural history of unresected or partially resected low grade gastric lymphoma treated medically. outline: this is a randomized study. patients are randomized to receive chlorambucil or placebo. patients receive omeprazole daily for 1 week. clarithromycin and tinidazole are administered twice daily for 1 week for the eradication of h. pylori infection. patients are assessed every 2-3 months by endoscopy. patients may receive a maximum of 3 courses of treatment every 2-3 months. other regimens may be used if full eradication of h. pylori is not achieved. patients who achieve complete response (eradication of h. pylori) are randomized to receive oral chlorambucil or placebo daily for 14 days. treatment is repeated every 28 days for 6 courses. patients are followed every 6 months for 2 years, then yearly thereafter. projected accrual: a total of 200 patients will be accrued for this study.

Eligibility criteria:
disease characteristics: endoscopically diagnosed, unresected, partially resected, or completely resected low grade (stage i) gastric lymphoma prior diagnosis of h. pylori infection no nodal metastases microbiological evidence of current h. pylori infection required no pathological evidence of enlarged abdominal lymph nodes by ct scan gastroscopic ultrasound evidence of enlarged nodes allowed, if ct scan normal patient characteristics: age: 16 and over performance status: not specified life expectancy: not specified hematopoietic: not specified hepatic: not specified renal: not specified prior concurrent therapy: biologic therapy: not specified chemotherapy: not specified endocrine therapy: not specified radiotherapy: not specified surgery: see disease characteristics

Keywords: stage i gastric cancer
analysis of circulating tumor markers in blood

Conditions: Cancer; Breast Cancer; Sarcoma; Lung Cancers; Glioma; Colon Cancer

Summary: the circulating tumoral biomarkers in the blood are the object of numerous researches for several decades. the potential clinical interests of these circulating biomarkers are diagnostic, prognostic, predictive of the efficiency of targeted therapies (according to the mutational profile of the cancer), and could allow the study of the mechanisms of resistance under process. in the multiplicity of these blood potential biomarkers joins a permanent evolution of the technological means used to detect them/to quantify, as well as to estimate their clinical utility.

the new major challenge in the research concerns the circulating biomarkers, which aim at replacing the molecular analyses on tumour tissue obtained by biopsy (for example the search for somatic mutations of cancer) by a simple blood test (liquid biopsy). the other current important challenge is to have an idea of the interest to analyse the kinetics of blood markers, in particular in answer to a clinical "event", either through the chemotherapy, a biopsy and / or surgery. there is almost no data in the literature on this aspect. it is very likely that the liberation in the blood of the blood tumoral markers is strongly dependent on medical interventions on the tumour. the study alcina 2 rests exactly on the principle of small cohorts, which correspond each to a clinical situation and/or a technique of different implemented detection, so as to generate data of feasibility and proof of concept. in case of success, statistical hypotheses will be necessary for the implementation of wider studies (being then the object of a specific approval by competent authorities).

Eligibility criteria:
inclusion criteria: 1. patient presenting an invasive tumoral pathology (proved or suspected), whatever is the location or the stage, 2. man or woman ≥ 18 years, 3. obtaining of the informed consent signed before any procedure of specific preselection on approval. exclusion criteria: 1. private persons of freedom or under guardianship, 2. patient whose regular follow-up is impossible for psychological, family, social or geographical reasons, 3. pregnant woman and/or breast-feeding, 4. unaffiliated patient to social protection system,
parent-adolescent interactions and adolescent development

Conditions: Substance Abuse

Summary: the purpose of this study is to observe parent-adolescent interactions and to examine the parenting behaviors and adolescent emotional and physiological responses that are associated with youth's substance use.

the study examines parenting behaviors and adolescent emotional responses during parent-adolescent interactions and whether these predict youth's current and future substance use over a 3 year follow-up.

Eligibility criteria:
inclusion criteria: * adolescent between ages 12-14 years exclusion criteria: * for adolescent, intelligence quotient (iq) \< 70 on standardized test, for parent, evidence of inability to read or write. * evidence of a psychotic disorder for parent or adolescent * diagnosis of autism or pervasive developmental disorder for adolescent, as determined by parent report in the screening. * for adolescent, current need for acute treatment of a psychiatric disorder, as determined by parent report in the study screening. * for adolescent and parent, inadequate english proficiency to comprehend task instructions
momentum-enabled treadling methodology to improve gait and enhance mobility

Conditions: Peripheral Arterial Disease

Summary: this is a pilot study of a new exercise device (tredlr) designed to facilitate repetitive ankle flexion/extension movements (i.e., "treadling") through a momentum-driven internal flywheel while seated. the specific goals of this project are to explore improvements in mobility and exercise capacity in individuals who treadle compared to a control group.


Eligibility criteria:
inclusion criteria: * be able to walk without an assistive aid (i.e., walker, cane) * have the capacity the provide written informed consent * have previously diagnosed peripheral arterial disease (by self-report) exclusion criteria: * lower extremity injury or fracture within the last 6 months * have a leg prosthesis * prisoners * individuals clearly lacking the capacity to provide informed consent * vestibular impairment
a study to evaluate sebacia microparticles in patients with inflammatory acne vulgaris

Conditions: Facial Acne Vulgaris

Summary: this study is proposed to evaluate sebacia microparticle treatment in patients with facial inflammatory acne vulgaris.


Eligibility criteria:
inclusion criteria: 1. male or female, 16-45 years of age. 2. moderate to moderately-severe facial inflammatory acne vulgaris 3. fitzpatrick skin phototype i-iii exclusion criteria: 1. pregnant, lactating, nursing or planning to become pregnant 2. tattoo in the treatment area 3. active skin disease, excessive scarring or excess facial hair in the treatment area 4. certain current or recent acne treatments 5. recent light treatments including intense pulsed light or other lasers, microdermabrasion or chemical peels in the treatment area 6. contraindicated for laser treatment, or is unable or unwilling to avoid excessive sun exposure or tanning bed use 7. known allergy to gold

Keywords: acne
gallant 4 tesaglitazar vs. glibenclamide

Conditions: Type 2 Diabetes

Summary: this is a 52-week randomized, double-blind, parallel-group, multi-center, active-controlled (glibenclamide) study of tesaglitazar in patients with type 2 diabetes, not adequately controlled on diet and lifestyle advice alone during the run-in period. the study comprises a 6 week placebo single blind run in period followed by a 52-week double blind treatment period and a 3-week follow-up period. tesaglitazar and glibenclamide will be titrated to optimal effect or highest tolerable dose during the first 12 weeks.


Eligibility criteria:
inclusion criteria: * provision of a written informed consent * men or women who are \>=18 years of age * female patients: postmenopausal, hysterectomized, or if of childbearing potential, using a reliable method of birth control * diagnosed with type 2 diabetes * treated with diet alone or treatment with a single oral antidiabetic agent or low doses of two oral antidiabetic agents exclusion criteria: * type 1 diabetes * new york heart association heart failure class iii or iv * treatment with chronic insulin * history of hypersensitivity or intolerance to any peroxisome proliferator-activated receptor agonist (like actos or avandia), fenofibrate, metformin or 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor (statin) * history of drug-induced myopathy or drug-induced creatine kinase elevation, liver enzyme elevations, neutropenia (low white blood cells) * creatinine levels above twice the normal range * creatine kinase above 3 times the upper limit of normal * received any investigational product in other clinical studies within 12 weeks * any clinically significant abnormality identified on physical examination, laboratory tests or electrocardiogram, which in the judgment of the investigator would compromise the patient's safety or successful participation in the clinical study
the effect of high-volume walking with visual cues (vc) in parkinson´s disease (pd)

Conditions: Parkinson´s Disease

Summary: people with disease (pd) tend to walk with short steps, decreased velocity, and increased stride time variability. short steps and increased variability are related to greater fall risk. in addition, concurrent performance of a cognitive task (dual-task (dt)) has marked effects on gait in people with pd which is considered to reflect an impaired automaticity of gait. objective: to investigate short and long term effects of high-volume walking with visual spatial cues (vsc) on gait variables, automaticity, and functional mobility, in people with parkinson´s disease (pd), compared with walking without vsc.


Eligibility criteria:
inclusion criteria: * a confirmed diagnosis of pd according to the uk parkinson´s disease society brain bank clinical diagnostic criteria (18) * \<80 years of age * community residing * hoehn and yahr (hy) stage 2-3 * mini mental state examination (mmse) score of \>23 * ability to walk without walking aids for a total of 20 minutes over a 30-minute period exclusion criteria: * major modifications of parkinson´s medication (madopar \>200 mg/d or \>20% increase in dopamine agonists) 3 weeks prior to baseline assessment * comorbidities or disabilities, which might influence walking * a history of brain surgery

Keywords: parkinson´s disease walking exercise automaticity dual task visual cues cueing neuroplasticity gait analysis
non-interventional study in pediatric patients treated with novocart inject in the knee

Conditions: Cartilage Disease

Summary: the study is a prospective, multicenter, single-arm non-interventional study to evaluate the efficacy, safety and health economics of novocart® inject in the treatment of cartilage defects of the knee in pediatric patients with radiologically proven closed epiphyseal growth plates.

in this non-interventional study novocart® inject, which is marketed in germany under a license according to section 4b of the amg, will be used in routine clinical practice according to the current authorized summary of product characteristics (smpc). as stated in this smpc, novocart® inject may only be used by physicians who are trained on the product. the treatment with novocart® inject requires two surgeries. during the first surgery cartilage tissue will be harvested arthroscopically and sent to tetec ag for novocart® inject manufacturing, then novocart® inject will be transplanted during a second surgery about 3 to 4 weeks later. all patients will be followed up for 5 years post novocart® inject implantation and data will be collected preoperatively and at 3, 6, 12, 18, 24, 36, 48 and 60 months as outlined at the end of this synopsis. novocart® inject post treatment rehabilitation should follow the recommendations given in the smpc and during product training. the primary and secondary variables (see below) will be assessed after a follow-up of 24 month post novocart® inject implantation (primary analysis). long-term data will be assessed after an additional 3 years follow-up (follow-up analysis). the collected data will be documented using dedicated case report forms (crfs) which are created by tetec ag.

Eligibility criteria:
inclusion criteria: * pediatric patients (\< 18 years of age at implantation) * closure of the epiphysis adjacent to the biopsy harvest site or the defect to be treated confirmed by an adequate imaging modality * localized full-thickness cartilage defect (icrs grade iii or iv) of the knee * medicinal indication for novocart® inject treatment exclusion criteria: see novocart inject smpc

Keywords: novocart inject cartilage defect pediatric patients knee cartilage injury
efficacy and safety trial of adu-s100 and pembrolizumab in head and neck cancer

Conditions: Metastatic Head and Neck Cancer; Recurrent Head and Neck Cancer

Summary: adu-cl-20 is an open-label, multicenter phase 2 clinical trial to evaluate the efficacy and safety of intratumoral adu-s100 (also referred to as miw815) administered with pembrolizumab in the first-line setting. the population will consist of adults with pd-l1 positive recurrent or metastatic hnscc.


Eligibility criteria:
inclusion criteria: * histological or cytological confirmation of recurrent or metastatic hnscc * measurable disease as defined by recist v1.1 * pd-l1 positive exclusion criteria: * diagnosis of recurrent or metastatic carcinoma of the nasopharynx, squamous cell carcinoma of unknown primary histology; or salivary gland or non-squamous histologies (e.g. mucosal melanoma) * disease amenable to local therapy with curative intent (surgery or radiation therapy with or without chemotherapy) * prior systemic anti-cancer therapy (use of chemotherapeutic agents, targeted small molecules, immunotherapy, or monoclonal antibodies) for the treatment of recurrent or metastatic hnscc
promiss: simvastatin prevents the contrast induced acute renal failure in patients with renal insufficiency undergoing coronary angiography

Conditions: Kidney Failure

Summary: the contrast induced kidney toxicity has been known to affect the mortality and morbidity in the patients undergoing coronary angiography. but the mechanism and therapeutic strategy for it is not well known. nowadays, it is reported that the n-acetylcysteine may have preventive effects for contrast induced kidney toxicity with its antioxidant effects.the statins have been reported to have many other effects other than the lipid lowering effect-including antioxidant effect, so we hypothesized that the antioxidant effect of simvastatin may prevent the contrast induced kidney toxicity.

the simvastatin may prevent the contrast agent induced acute renal failure in the patients with underlying renal insufficiency who is undergoing the coronary angiography. the effect may derive from the antioxidant function of simvastatin.

Eligibility criteria:
inclusion criteria: * angina patients * patients who is required the coronary catheterization * creatinine clearance rates ≤60 ml/min using the cockcroft-gault formula patients who undergo coronary catheterization * age of 19 or over 19 exclusion criteria: * pregnancy * lactation * having received contrast media within 7 days of study entry * emergent coronary angiography * acute renal failure * end-stage renal disease requiring dialysis * history of hypersensitivity reaction to contrast media * cardiogenic shock * pulmonary edema * multiple myeloma * mechanical ventilation * parenteral use of diuretics * use of n-acetylcysteine * use of metformin or nonsteroidal anti-inflammatory drugs within 48 hours of the procedure.

Keywords: kidney failure contrast media prevention simvastatin